Autoantibodies against GLEA2 and PHF3 in glioblastoma: Tumor-associated autoantibodies correlated with prolonged survival

International Journal of Cancer

Volumn 117, Issue 3, 2005, Pages 456-459

  Pallasch, Christian Philipp ^a   Struss, Anne Katrin ^a   Munnia, Angela ^a   König, Jochem ^a   Steudel, Wolf Ingo ^a   Fischer, Ulrike ^a   Meese, Eckart ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

GLEA2; Glioblastoma; PHF3; Prognosis; SEREX

Indexed keywords

ANTIGEN GLEA1; ANTIGEN GLEA2; ANTIGEN PHF3; AUTOANTIBODY; COMPLEMENTARY DNA; IMMUNOGLOBULIN G; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; BACTERIOPHAGE LAMBDA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SEROLOGICAL IDENTIFICATION OF RECOMBINANTLY EXPRESSED TUMOR ANTIGEN; SEROLOGY; SERUM; STEROID THERAPY; SURVIVAL TIME;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TIME FACTORS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 26444586707     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20929     Document Type: Article

References (29)

1. Daumas-Duport C, Scheithauer B, O'Fallon J. Grading of astrocytomas. Cancer 1988;63:2152-65.
2. Kleihues P, Burger PC. Tumors of the nervous system. Lyon: IARC Press, 2000.29-39.
3. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25.
4. Balesaria S, Brock C, Bower M, Clark J, Nicholson SK, Lewis P, de Sanctis S, Evans H, Peterson D, Mendoza N, Glaser MG, Newlands ES, Fisher RA. Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas. Br J Cancer 1999;81:1371-7.
5. Korshunov A, Golanow A, Sychewa R, Pronin I. Prognostic value of tumour associated antigen immunoreactivity and apoptosis in cerebral glioblastomas: an analysis of 168 cases. J Clin Pathol 1999;52:2230-5.
6. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG 2nd, Aldape K. Analysis of complex relationships between age, p53, epidermal growth factor, and survival in glioblastoma patients. Cancer Res 2001;61:1122-8.
7. Jung V, Romeike BFM, Henn W, Feiden W, Moringlane JR, Zang KD, Urbschat S. Evidence of focal genetic microheterogeneity in glioblastoma multiforme by area-specific CGH on microdissected cells. J Neuropathol Exp Neurol 1999;58:993-9.
8. Loeper S, Romeike BFM, Heckmann N, Jung V, Henn W, Feiden W, Zang KD, Urbschat S. Frequent mitotic errors in tumor cells of genetically microheterogenous glioblastomas. Cytogenet Cell Genet 2001;94:1-8.
9. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci 1996;92:1810-3.
10. Brass N, Racz A, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E. Translation factor eIF4gamma is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Human Mol Genet 1997;6:33-9.
11. Jager E, Stockert E, Zidianakis Z, Chen YT, Karbach J, Jager D, Arand M, Ritter G, Old LJ, Knuth A. Humoral immune response of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999;84:506-10.
12. Scanlan MJ, Gordan JD, Williamson B, Stockert E, Bander NH, Jongeneel V, Gure AO, Jager D, Jager E, Knuth A, Chen YT, Old LJ. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer 1999;83:456-64.
13. Stockert E, Jäger E, Chen YT, Scanlan M, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
14. Eichmüller S, Usener D, Dummer R, Stein A, Thiel D, Schadendorf D. Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci 2001;98:629-34.
15. Scanlan MJ, Chen YT, Williamson B, Gure AO, Stockert E, Gordan JD, Tureci O, Sahin U, Pfreundschuh M, Old LJ. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.
16. Fischer U, Strass AK, Hemmer D, Pallasch CP, Steudel WI, Meese E. Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls. Clin Exp Immunol 2001;126:206-13.
17. Struss AK, Romeike BF, Munnia A, Nastainczyk W, Steudel WI, Konig J, Ohgaki H, Feiden W, Fischer U, Meese E. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme. Oncogene 2001;20:4107-14.
18. Abu-Shakra M, Buskila D, Ehrenfeld M, Conrad K, Shoenfeld Y. Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis 2001;60:433-41.
19. Mack U, Ukena U, Montenarh M, Sybrecht GW. Serum anti-p53 antibodies in patients with lung cancer. Oncol Rep 2000;7:669-74.
20. Metcalfe S, Wheeler TK, Picken S, Negus S, Milner AJ. P53 autoantibodies in 1006 patients followed up for breast cancer. Breast Cancer Res 2000;2:438-43.
21. Lai CL, Tsai CM, Tsai TT, Kuo BI, Chang KT, Fu HT, Perng RP, Chen JY. Presence of serum anti-p53 antibodies is associated with pleural effusions and poor prognosis in lung cancer patients. Clin Cancer Res 1998;4:3025-30.
22. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J. Small-cell lung cancer, paraneolastic cerebellar degeneration and the Lambert-Eaton syndrome. Brain 1997;120:1279-300.
23. Posner JB, Dalmau JO. Paraneoplastic syndromes of the nervous system. Clin Chem Lab Med 2000;38:117-22.
24. Blaes F, Klotz M, Sträub U, Kalweit G, Schimrigk K, Schäfers HJ. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann Thor Surg 2000;69:254-8.
25. Syrigos KN, Charalambopoulos A, Pliarchopoulou K, Varsamidakis N, Machairas A, Mandrekas D. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res 2000;20:4351-3.
26. Martin-Achard A, Tribolet N, Louis JA, Zander E. Immune complexes associated with brain tumours: correlation with prognosis. Surg Neurol 1980;13:161-3.
27. Tan EM. Autoantibodies in pathology and cell biology. Cell 1991;67:841-2.
28. Ayyoub M, Stevanovic S, Sahin U, Guillaume P, Servis C, Rimoldi D, Valmori D, Romero P, Cerrottini JC, Rammensee HG, Pfreundschuh M, Speiser D, et al. Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma. J Immunol 2002;168:1717-22.
29. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-70.